Non-participation in early intervention with inhaled steroids in asthma and chronic obstructive pulmonary disease (COPD): The role of 'fear of steroids'. Results of the 'DIMCA' study by Grunsven, P.M. van et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
MONDAY, SEPTEMBER 22ND 1997
Results: This approach resulted in a significant enhancement of the quality of care 
criteria analyzed:
Documented in the medical record Before (n = 115) After (n= 93) P
Recent facts of the disease 79 (69%) 88 (95%) <0.001
Presence of follow-up 32 (28%) 84 (90%) <0.001
Breathing rate on arrival 42 (36%) 54 (58%) 0.002
PEF before treatment 22(19%) 82 (88%) <0.001
PEF after treatment 8 (7%) 77 (83%) <0.001
Steroid therapy 58 (50%) 71 (76%) <0.001
Follow-up after ED discharge 19/90 (21%) 35/47 (74%) <0.001
Discussion and Conclusion: Implementation of locally developed guidelines with 
the participation of all healthcare personal was time consuming but had a sig­
nificant impact on the ED management of asthma patients. This program should 
be continued to even further increase the quality of patient care. The impact on 
clinical outcome is currently being assessed.
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Undertreatment in asthmatic outpatients with mild bronchial obstruction 
B. Farabollini, M.S. Garritani, S. Pucci, M.B. Bil6, L. Antonicelli, E Bonifazi. 
AUergy Respiratory Unit, Hospital Umberto 1, Ancona, Italy
Undertreatment is one of the reasons for symptoms* sleep disturbance and lim­
itation of activities in asthmatics. Inhaled anti-inflammatory drugs, in particular 
steroids, are very effective in controlling asthma symptoms in patients of al! ages 
and severity.
The aim of our study was to evaluate, in asthmatics with mild bronchial obstruction, 
the difference between the domiciliary treatments carried out by outpatients (Opts) 
and that prescribed by the specialists (Sps) based on the severity of symptoms 
referred.
A retrospective study of 112 consecutive Opts (51 males, 61 females; mean age: 
29 yrs, range; 13-63) with % p FEV1 > 70 (mean: 98%, range: 70-132%) was 
performed.
The patients’ histories and disease severity score in the previous four weeks (DSS) 
were investigated and the therapy (level 0-4) used by the Opts and prescribed by 
the Sps was compared.
Spearman’s rank correlation was used for nonparametric data.
Only 6 out of 112 (5%) Opts did not report symptoms of asthma (DSS equal to 0) 
after domiciliary treatment.
We found a significant difference between the therapy used by Opts at home and 
that prescribed by the Sps (median; home therapy = 0.5; Sps ~ 2; p < 0.0001, 
Wilcoxon test), even if a correlation did exist between them (r-0,39, p < 0.0001), 
The total DSS was not associated with the therapy used by the Opts, unlike that of 
the Sps (r = 0.24, p < 0.001).
We found a significant correlation between the domiciliary therapy and day symp­
toms only (r = 0.20, p < 0.03) and shortness of breath due to exertion (r = 0.19, 
p < 0.04); on the contrary there was significant correlation between Sps’ therapy 
and day symptoms (r = 0.22, p < 0.01), shortness of breath due to exertion (r = 
0.22, p < 0.01) and also night symptoms (r = 0.21, p < 0.02).
In conclusion, in asthmatics with mild bronchial obstruction: 1) the treatment 
used by the Opts at home is different from that prescribed by the Sps and the 
their treatment level is indicated by the severity of day symptoms and shortness 
of breath due to exertion; 2) the anti-inflammatory therapy is not used regularly, 
therefore the night symptoms are probably still present.
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Non-participation in early intervention with inhaled steroids in asthma and 
chronic obstructive pulmonary disease (COPD): The role of ‘fear of steroids*. 
Results of the ‘DIMCA’ study
P.M. van Grunsven, C.P. van Schayck, H.J.M. van Kollenburg, K. van Bosheide, 
II. J.M. van den Hoogen, J. Molema1, C, van Weel. Dept. of General Practice 
and Social Medicine, University of Nijmegen, The Netherlands, lDept. of 
Pulmonology, University of Nijmegen, The Netherlands
Treatment of chronic airflow obstruction with inhaled steroids at an early stage has 
shown to preserve the lung function. However, long-term treatment with inhaled 
steroids may cause local and systemic adverse effects. We tested the hypothesis that 
‘fear of steroids’ may be an important reason of non-participation in the ‘DIMCA’ 
project, a Detection, early Intervention and Monitoring program on COPD and 
Asthma. 1749 Randomly selected adult subjects derived from 10 general practices 
were invited to a screening program to detect asthma or COPD. 604 Subjects 
were selected on the basis of the presence of bronchial obstruction, reversibility 
of obstruction and bronchial symptoms. After a two-year monitoring period 241 
patients with an increased lung function decline or bronchial hyperresponsiveness 
were invited to participate to an early intervention trial with inhaled steroids. Non­
participants were sent a questionnaire about the reason(s) of non-participation. 
Together the screening, monitoring and intervention part of the study showed on 
average 28% non-participants. The most frequent reason for non-participation was 
a general resistance to take medication daily (50% of the non-participants of the 
intervention trial). Remarkably, a specific ‘fear of steroids’ was a reason for denial 
in only 8.6% of these non-participants. It was concluded that ‘fear of (inhaled) 
steroids’ seemed not to be an obstacle for early treatment of asthma and COPD.
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The clinical control of asthma after adding airway hyperresponsivcness 
(AHR) to the guides of long-term therapy. A two-year randomised trial 
J.K. Sont 1,2t L.N.A. Willems1, E.H. Bel1, C.E. Evertse *, J.P. Vandenbroucke2, 
P.J. Sterk1, the AMPUL Study Group. Departments o f1 Pulmonology; 2Clinical 
Epidemiology, Leiden University Medical Centre, The Netherlands
According to present guidelines (GINA), the level of anti-inflammatory treatment 
for asthma is solejy based on symptoms and lung function. In a randomised par­
allel design we investigated whether a treatment strategy aimed at reducing AHR 
(strategy B) on top of improving symptoms, FEVj and peak flow (PEF) variability 
(strategy A) leads to more effective control. 75 Non-smoking adults with mild to 
moderate atopic asthma (18-50 yr, 23 newly detected; FEV[ (mean dr SD): 92 ± 
15 %pred) visited the chest physician, every 3 months during 2 yrs. Prior to each 
visit, methacholine PC20 (baseline: geom. mean ± SD: 0.63 mg/ml ± 2.11 DD) 
was assessed and the subjects recorded asthma symptoms, -agonist usage and 
morning + evening PEF on a diary card, during 14 days, At each visit, in both 
strategies, controller medication with inhaled corticosteroids and/or prednisone (4 
Levels; no steroids, 400,800,1600 ¿ig/day+2 wk prednisone) was adjusted accord­
ing to a stepwise approach similar to GINA, and to which 4 corresponding classes 
of AHR were added. In 62% of all instances, AHR-class indicated the need for an 
increased medication level, which was only applied in strategy B. Improvements 
in FEV[ and morning PEF (% personal best) were more pronounced in strategy B 
vs A (B: 5.0 %pred, 9.0% and A: 0.1%pred and 3.5 1/s, respectively; p < 0.05). 
The exacerbation rate was 2.2 times lower in strategy B vs A (Cox regression; p 
< 0.05). Furthermore, individual standard deviations over the last 1.5 yr period 
for FEV|%pred, morning PEF, PEF-variability and PC20 were smaller in strategy 
B vs A (MANOVA: p < 0.05). We conclude that a treatment strategy aimed at 
reducing BHR on top of improving symptoms, FEVj and PEF-variability leads to 
more effective control of asthma, resulting in fewer exacerbations and less variable 
airflow limitation. This implicates a role for monitoring AHR in the long-term 
management of asthma.
This abstract is funded by: The Netherlands Asthma Foundation 
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Use of a simple patient focussed asthma morbidity score
L.D. Rimminglon, L. Aronoffsky, A. Mowatt, E. Wharburton, I. Ryland,
M.G. Pearson. Aintree Chest Centre, Liverpool and Dept Rehabilitation, Univ of 
Salford, UK
Established and validated questionnaires have been shown to be useful research 
tools with which to assess asthma morbidity (Juniper 1993), but they too time 
consuming for routine clinical practice. We have used four questions that the 
doctor would usually ask in each consultation (covering nights waking, reliever 
inhaler use, daytime wheezing and disruption of activities) to produce an 8 point 
score that requires no extra time from the clinician. We have assessed this short 
questionnaire score (Q score) with the Juniper morbidity score (total score and 
symptom score), with levels of PEF, and with the UK asthma guidelines treatment 
step in 81 patients randomly selected from 3 general practices (mean (SD), age 44 
(12), 26 male, PEF 345 (138), FEV1 2.2 (0.9)) and repeated the observations two 
weeks later in a subset of 21 patients.
The paired observations showed that both Juniper (r = 0.87) and Qscorc (r = 0.79) 
were repeatable with similar variability. The Qscore was negatively correlated with 
the Juniper symptom score (r = 0.79, p < 0.01) and total score (r = —0.73, p < 
0.01) and both Qscore and Juniper correlated with level of resting FEVl (Q: r = 
0,44, J: r = —0.42) and with the severity of asthma as indicated by the treatment 
step (Q: r = 0.47, J: r = —0.36. all p < 0.01) although there was considerable 
scatter for the latter. The Qscore correlates well with both the established longer 
questionnaire and also shows similar relationships to lung function and to severity. 
If it also shows sensitivity to changes in asthma status over the next year it 
may provide a practical tool with which to estimate asthma morbidity in routine 
practice.
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Effects of patient education to the life quality in asthma patients: 3 years 
experience
E. Akkaya, A. Yrlmaz, F. Ece, B. Bayramgiirler, A, Baran, A. Akakga. SSK 
Stireyyapaga Center for Chest Diseases and Thoracic Surgery, Istanbul, Turkey
Acceptance and application of the International Asthma Report by most countries 
made asthma therapy more than a simple prescription. It may be expected that 
patient education in addition to drug treatment will improve the life quality and 
prognosis of patients. For this reason, we studied randomly selected 25 cases 
(group I) that given special education for 1 year and randomly selected 27 cases
Group1 Group II
%KS 77.6 ± 12.0° 53.8 ± 10.5°
% DS 97.4 ± 6.10r 92.9 ± 15.6r
Aas score 0.52 ± 0.87* 0.85 ± 1.20*
N.SS 1.2QÌ0.60 1.60 ± 0.90'
D.SS 0.32 ± 0.62« 0.81 ± 1.21“
QOL 6.16 ±1.350 5.52 ± 1.81*
° p = 0,0000 T p > 0.05 * p < 0.05 ' p = 0.07 a 0.05 0 p = 0.0001
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